title: Eisenmenger syndrome: recent advances in pharmacotherapy.
abstract: Over the last decade advanced therapies for the management of pulmonary arterial hypertension have been introduced. These agents have also been effective in reducing pulmonary vascular resistance in patients with Eisenmenger syndrome. Specific guidelines focusing on modern therapies for Eisenmenger syndrome however do not exist to date. More recently, clinical trials in patients with Eisenmenger syndrome demonstrated a significant clinical improvement with favorable safety and tolerability profile. This review aims to summarize newly reported pharmacological agents used in patients with Eisenmenger syndrome.
authors.forename: Sarmad
authors.initials: S
authors.lastname: Said
authors.forename: Mateo
authors.initials: M
authors.lastname: Porres-Aguilar
authors.forename: Mateo
authors.initials: M
authors.lastname: Porres-Munoz
authors.affiliation: Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center at El Paso, 4800 Alberta Avenue, El Paso, Texas, USA 79905. sarmad.said@ttuhsc.edu.
authors.forename: Debabrata
authors.initials: D
authors.lastname: Mukherjee
mesh_terms: D004541:Eisenmenger Complex / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D065128:Endothelin Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011453:Prostaglandins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins